Navigation Links
Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting
Date:5/4/2008

is may include upper respiratory tract infection, ear infection, fever, and runny nose. In children born with heart problems, Synagis was associated with reports of low blood oxygen levels and abnormal heart rhythms. Synagis should not be used in patients with a history of a severe prior reaction to Synagis or its components. Side effects, such as, skin reactions around the area where the shot was given (like redness, swelling, warmth, or discomfort) can also occur.

The pivotal trial for Synagis was called the IMpact trial and comprised a total of 1,502 children who were randomized (500 placebo, 1,002 Synagis) in a double-blind, placebo-controlled protocol where 1,486 children completed the study's follow-up.

In the IMpact trial, monthly prophylaxis with Synagis via intramuscular injections was associated with a 55-percent reduction in hospitalization as a result of RSV (p=<0.001). Reductions were observed in both children with bronchopulmonary dysplasia (38 percent reduction) and premature children without BPD (78 percent reduction). Approximately 50 percent of the children in the analysis had BPD.

For full prescribing information for Synagis, see the company's website at: http://www.medimmune.com/products/synagis/index.asp.

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease, and neuroscience. With approximately 3,000 employees worldwide and headquarters in Maryland, MedImmune is wholly owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune's website at http://www.medimmune.com'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , June 29, 2015 ... addition of the "Pharmaceutical Grade Sodium Chloride Market ... to 2019" report to their offering. ... witness a CAGR of 6.9% between 2014 and 2019 ... to reach 690 KT by 2019. The ...
(Date:7/6/2015)... BOULDER, Colo. , July 6, 2015 /PRNewswire/ ... inhibitor, encorafenib, was showcased this past weekend at ... during an oral presentation.  At the meeting, data ... preliminary data from a 100-patient randomized Phase 2 ... encorafenib and cetuximab, an EGFR inhibitor, with or ...
(Date:7/6/2015)...   Cepheid (Nasdaq: CPHD ) today announced ... second quarter ended June 30, 2015 on Thursday, July ... The Company will host a management presentation at ... to discuss the results.  To access the live webcast, ... least 15 minutes before the scheduled start time to ...
Breaking Medicine Technology:Global Pharmaceutical Grade Sodium Chloride Market Report 2015 2Global Pharmaceutical Grade Sodium Chloride Market Report 2015 3Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 2Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 3Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 4
... N.J., Jan. 6, 2012  Tris Pharma, an emerging ... its core technology patent for its OralXR+™ platform. ... substantial estate filed by Tris Pharma and covers ... comprising drug-ion exchange resin complexes.  ...
... (Nasdaq: ENDP ) announced today it has ... BioDelivery Sciences International (Nasdaq: BDSI ) for ... transmucosal form of buprenorphine, a partial mu-opiate receptor agonist, ... is currently in phase III trials for the treatment ...
Cached Medicine Technology:Tris Pharma Announces US Patent Grant Covering Platform Technology 2Endo Pharmaceuticals and BioDelivery Sciences International Sign Licensing Agreement for BEMA Buprenorphine 2
(Date:7/6/2015)... ... July 06, 2015 , ... Cancer Hope Network (CHN) has ... medical professionals to chat with the CHN patient services team and connect with ... diagnosis is often the most traumatic experience of a person’s life,” said CHN ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... & Associates has once again teamed up with Family Emergency Shelter Coalition (FESCO) ... move toward self-sufficiency. FESCO was created especially to provide emergency services and support ...
(Date:7/6/2015)... ... 06, 2015 , ... With a new community program in the Livonia, Canton ... and announced a new charity campaign to raise funds in support of the health ... Livonia Save Our Youth is a coalition created especially to educate and empower teens, ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... Dr. Lawrence ... Washington, DC, area patients. Kybella is a non-surgical method to dissolve fat ... of reducing moderate to severe fat deposits under the chin, commonly known as a ...
(Date:7/6/2015)... Kingdom (PRWEB) , ... July 06, 2015 , ... Diabetes ... could help. More than 29 million Americans have diabetes, the majority of which are ... million U.S. adults or more than one in three, have prediabetes (abnormally high blood ...
Breaking Medicine News(10 mins):Health News:Cancer Hope Network Launches Upgraded Website to Support Cancer Patients, Caregivers 2Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 2Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 3Health News:Bowker Insurance Group and Nonprofit Livonia Save Our Youth Initiate New Charity Campaign in Livonia, MI to Provide for The Health and Safety of The Communities’ Youth 2Health News:Bowker Insurance Group and Nonprofit Livonia Save Our Youth Initiate New Charity Campaign in Livonia, MI to Provide for The Health and Safety of The Communities’ Youth 3Health News:Rockville, MD Practice Now Offering New FDA-Approved Non-Surgical Double Chin Treatment 2Health News:115 Million in the U.S. could beat diabetes with the help of a new app 2
... people "tear up," but a new study led by University of ... containing an ingredient derived from hot chili peppers ( Capsicum annum ... The study, which appears in the August 2011 edition ... use of the Capsicum annum nasal spray to a ...
... cyclase C (GCC) has been established as a suppressor ... Thomas Jefferson University suggests it may also help ... Reporting in the August 25 online issue of ... M.D., Ph.D., chairman of the Department of Pharmacology ...
... HealthDay Reporter , THURSDAY, Aug. 25 (HealthDay News) -- An ... finds that children,s vaccines are typically safe, with bad reactions ... problems. The IOM committee also agreed that there is ... later onset of conditions such as autism or type 1 ...
... Aug. 24, 2011 -- Heart rate and blood pressure ... in children. In a new study by researchers at Wake ... a condition known as orthostatic intolerance (OI), which causes dizziness ... shown to reduce debilitating chronic nausea in patients., "There seems ...
... , WASHINGTON An analysis of more than 1,000 ... by or clearly associated with vaccines. A committee ... review the scientific literature on possible adverse effects of ... including seizures, inflammation of the brain, and fainting -- ...
... THURSDAY, Aug. 25 (HealthDay News) -- Federal officials on Thursday ... make emergency preparations for Hurricane Irene, a "category 3" storm ... current forecast places the center of Irene just off the ... Monday morning, according to the U.S. National Weather Service. ...
Cached Medicine News:Health News:Could a tumor suppressor also fight obesity? 2Health News:U.S.-Mandated Report Finds Vaccines Safe for Kids 2Health News:U.S.-Mandated Report Finds Vaccines Safe for Kids 3Health News:U.S.-Mandated Report Finds Vaccines Safe for Kids 4Health News:Heart may hold key to unexplained nausea in youths 2Health News:Few health problems are caused by vaccines, IOM report finds 2Health News:Few health problems are caused by vaccines, IOM report finds 3Health News:East Coast Urged to Prepare as Hurricane Irene Approaches 2
White Standard Girdle...
Below Knee Girdle, High Waist...
Bodyshaper For Men...
Torso Brief Bodysuit V-BA85...
Medicine Products: